Swiss National Bank
ZNTL icon

Swiss National Bank’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Swiss National Bank’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-104,700
Closed -$428K – 2486
2024
Q2 		$428K Buy
104,700
+7,300
+7% +$81.5K ﹤0.01% 2433
2024
Q1 		$1.54M Hold
97,400
– – ﹤0.01% 1985
2023
Q4 		$1.48M Sell
97,400
-11,000
-10% -$160K ﹤0.01% 2014
2023
Q3 		$2.17M Sell
108,400
-14,200
-12% -$360K ﹤0.01% 1788
2023
Q2 		$3.46M Buy
122,600
+24,100
+24% +$578K ﹤0.01% 1532
2023
Q1 		$1.69M Sell
98,500
-11,500
-10% -$233K ﹤0.01% 1943
2022
Q4 		$2.22M Buy
110,000
+2,000
+2% +$43K ﹤0.01% 1830
2022
Q3 		$2.34M Hold
108,000
– – ﹤0.01% 1758
2022
Q2 		$3.04M Buy
108,000
+54,400
+101% +$1.44M ﹤0.01% 1634
2022
Q1 		$2.47M Buy
53,600
+4,000
+8% +$216K ﹤0.01% 1913
2021
Q4 		$4.17M Buy
49,600
+4,000
+9% +$310K ﹤0.01% 1577
2021
Q3 		$3.04M Buy
45,600
+800
+2% +$46.1K ﹤0.01% 1777
2021
Q2 		$2.38M Buy
44,800
+3,000
+7% +$161K ﹤0.01% 1987
2021
Q1 		$1.81M Buy
41,800
+1,100
+3% +$47.4K ﹤0.01% 2062
2020
Q4 		$2.11M Buy
+40,700
New +$1.84M ﹤0.01% 1872

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Swiss National Bank's ZNTL Position: Q3 2024 in Review

Swiss National Bank sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 104,700 shares — an estimated $428K sold.

Swiss National Bank first reported a position in ZNTL in Q4 2020 and held it in 15 quarters. The position peaked at $4.17M in Q4 2021. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Swiss National Bank reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Swiss National Bank sold 104,700 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $428K.
  • Swiss National Bank first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 15 quarters.
  • Swiss National Bank's Zentalis Pharmaceuticals position peaked at $4.17M in Q4 2021.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Swiss National Bank's 13F filing for Q3 2024, filed 7 Nov 2024.